Improved carnosic acid congener compounds for Alzheimer’s disease
Improved carnosic acid congener compounds for Alzheimer’s disease
批准号:
10601159
负责人:
JAMES W LARRICK
金额:
$32.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-30 至 2024-08-31
关键词:
ABCC1 geneAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease patientAmericanAmyloid beta-ProteinAnimal ModelAnimalsAnti-Inflammatory AgentsAntioxidantsBehavioralBindingBiological AvailabilityBrainCarbamatesCatalytic DomainCatecholsCell NucleusClinical TrialsCysteineCystineCytoplasmic ProteinDataDementiaDevelopmentDiseaseDiterpenesDoseDrug ExposureDrug KineticsEffectivenessElementsEnzymesEstersFailureFamilyGCLC geneGCLM geneGenerationsGenesGenetic TranscriptionGlutamatesGlutathione DisulfideGlutathione S-TransferaseGoalsHalf-LifeHerbHistologicHumanImpaired cognitionIn VitroIncidenceLeadLettersLigaseModelingMonitorNADPNeurodegenerative DisordersNeurofibrillary TanglesNeuronsNitrogenOralOxidative StressOxidoreductaseOxygenPathway interactionsPatientsPeptidesPharmaceutical PreparationsPhasePhenolsProdrugsPromoter RegionsProteinsPublic HealthQuinonesReactionRosemarySenile PlaquesSideSulfhydryl CompoundsSynapsesTXN geneTherapeuticToxic effectTransgenic MiceWorkabeta toxicityaging populationassay developmentburden of illnesscare costseffective therapyglutathione peroxidasehydroxyl groupimprovedin vitro Assaymouse modelmutantneuron lossnitrosative stressnovelnovel therapeuticsoAβperoxiredoxin 2pre-clinicalsalvinside effectsmall molecule therapeuticssynaptic functiontau Proteinstau aggregationthioredoxin reductasetranscription factortransgenic model of alzheimer disease
中文摘要
改良鼠尾草酸同类化合物治疗阿尔茨海默病
英文摘要
Improved carnosic acid congener compounds for Alzheimer’s disease
Abstract
Five million Americans currently suffer the devastating consequences of Alzheimer’s disease (AD), and
unfortunately, the numbers are increasing due to our aging population. While some treatments can lower disease
burden, there is no cure and all patients inevitably succumb. Cost of care for treatment of AD is expected to
reach $1.1 trillion without an effective treatment or a change in the trajectory of AD. Loss of synaptic function is
associated with cognitive decline in AD and is a better predictor of cognitive loss in AD than plaques or tangles.
Damage to neurons occurs at least partially through generation of oxidative and nitrosative stress, due to
excessive generation of reactive oxygen/nitrogen species (ROS/RNS) triggered by oligomeric amyloid beta (Aβ)
peptide and downstream hyperphosphorylation and aggregation of tau protein (pTau). Carnosic acid (CA), a
phenolic diterpene particularly abundant in the herb rosemary (Rosmarinus officinalis), protects neurons and
synapses from damage caused by oxidative stress. In addition to direct antioxidant activity, CA belongs to a
class of “pro-electrophiles” that activate the Keap1/Nrf2 pathway, upregulating transcription of a broad range of
phase II antioxidant and anti-inflammatory proteins through the antioxidant responsive element (ARE). In vitro,
CA protects neurons from Aβ toxicity. CA treatment ameliorates various behavioral and histological deficits in
transgenic AD model mice, while showing no significant side effects. During this Phase 1 project, we will develop
a novel, proprietary CA-derived therapeutic with improved bioavailability to achieve therapeutic levels
with once daily dosing. We will then evaluate this novel compound as a therapeutic small molecule for the
treatment of AD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
-
批准号:10759808
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2023
-
负责人:JAMES W LARRICK
-
依托单位:
Therapy for ectopic calcification in pseudoxanthoma elasticum
-
批准号:10763057
-
项目类别:
-
资助金额:$28.58万
-
财政年份:2023
-
负责人:JAMES W LARRICK
-
依托单位:
Pan-COVID Therapeutic
-
批准号:10546550
-
项目类别:
-
资助金额:$27.58万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical
-
批准号:10704207
-
项目类别:
-
资助金额:$27.58万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
Therapeutic antibody for anorexia nervosa
-
批准号:10480127
-
项目类别:
-
资助金额:$25.96万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
Therapeutic antibody for hyperemesis gravidarum
-
批准号:10601709
-
项目类别:
-
资助金额:$30.08万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
Advancing a novel therapy for preeclampsia
-
批准号:10478384
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
Inhibiting GPR146 in hypercholesterolemia
-
批准号:10255573
-
项目类别:
-
资助金额:$24.97万
-
财政年份:2021
-
负责人:JAMES W LARRICK
-
依托单位:
Therapeutic antibody for cancer-associated cachexia
-
批准号:10244794
-
项目类别:
-
资助金额:$25.23万
-
财政年份:2021
-
负责人:JAMES W LARRICK
-
依托单位:
Novel anti-fibrotic therapy for IPF
-
批准号:9906133
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2020
-
负责人:JAMES W LARRICK
-
依托单位:
Targeting TGF-beta activation in tumors
-
批准号:9907773
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2019
-
负责人:JAMES W LARRICK
-
依托单位:
Novel therapy for Goodpasture syndrome
-
批准号:9458269
-
项目类别:
-
资助金额:$22.44万
-
财政年份:2017
-
负责人:JAMES W LARRICK
-
依托单位:
Novel Aminoadamantane Nitrates for the Treatment of Neurological Diseases
-
批准号:9045917
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2016
-
负责人:JAMES W LARRICK
-
依托单位:
Novel NMDA Receptor Antagonists for Beta Cell Rescue
-
批准号:9047082
-
项目类别:
-
资助金额:$22.46万
-
财政年份:2015
-
负责人:JAMES W LARRICK
-
依托单位:
Novel therapy for Netherton syndrome
-
批准号:8977549
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2015
-
负责人:JAMES W LARRICK
-
依托单位:
Novel Therapy for Tumor-induced Osteomalacia
-
批准号:8646263
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:JAMES W LARRICK
-
依托单位:
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering
-
批准号:8978257
-
项目类别:
-
资助金额:$49.98万
-
财政年份:2014
-
负责人:JAMES W LARRICK
-
依托单位:
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering
-
批准号:9089847
-
项目类别:
-
资助金额:$45.58万
-
财政年份:2014
-
负责人:JAMES W LARRICK
-
依托单位:
Point-of-care immunoassay panel for cardiotonic steroids
-
批准号:8779926
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:JAMES W LARRICK
-
依托单位:
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering
-
批准号:8713600
-
项目类别:
-
资助金额:$22.43万
-
财政年份:2014
-
负责人:JAMES W LARRICK
-
依托单位: